BR112015006656A8 - composições e métodos para o tratamento de insuficiência cardíaca em pacientes diabéticos - Google Patents
composições e métodos para o tratamento de insuficiência cardíaca em pacientes diabéticos Download PDFInfo
- Publication number
- BR112015006656A8 BR112015006656A8 BR112015006656A BR112015006656A BR112015006656A8 BR 112015006656 A8 BR112015006656 A8 BR 112015006656A8 BR 112015006656 A BR112015006656 A BR 112015006656A BR 112015006656 A BR112015006656 A BR 112015006656A BR 112015006656 A8 BR112015006656 A8 BR 112015006656A8
- Authority
- BR
- Brazil
- Prior art keywords
- heart failure
- methods
- compositions
- treatment
- diabetic patients
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- C—CHEMISTRY; METALLURGY
- C13—SUGAR INDUSTRY
- C13K—SACCHARIDES OBTAINED FROM NATURAL SOURCES OR BY HYDROLYSIS OF NATURALLY OCCURRING DISACCHARIDES, OLIGOSACCHARIDES OR POLYSACCHARIDES
- C13K13/00—Sugars not otherwise provided for in this class
- C13K13/002—Xylose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1883—Neuregulins, e.g.. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C13—SUGAR INDUSTRY
- C13K—SACCHARIDES OBTAINED FROM NATURAL SOURCES OR BY HYDROLYSIS OF NATURALLY OCCURRING DISACCHARIDES, OLIGOSACCHARIDES OR POLYSACCHARIDES
- C13K13/00—Sugars not otherwise provided for in this class
- C13K13/007—Separation of sugars provided for in subclass C13K
Abstract
composições e métodos para o tratamento de insuficiência cardíaca em pacientes dibéticos a presente invenção proporciona a utilização da proteína neuregulina para a preparação de medicamentos para prevenir, tratar ou retardar insuficiência cardíaca em seres humanos e métodos para prevenir, tratar ou retardar insuficiência cardíaca em seres humanos utilizando a dita medicação.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2012/001353 WO2014056121A1 (en) | 2012-10-08 | 2012-10-08 | Compositions and methods for treating heart failure in diabetic patients |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112015006656A2 BR112015006656A2 (pt) | 2018-11-13 |
BR112015006656A8 true BR112015006656A8 (pt) | 2020-01-21 |
Family
ID=50476845
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112015006656A BR112015006656A8 (pt) | 2012-10-08 | 2012-10-08 | composições e métodos para o tratamento de insuficiência cardíaca em pacientes diabéticos |
Country Status (9)
Country | Link |
---|---|
US (2) | US10894815B2 (pt) |
EP (1) | EP2903632A4 (pt) |
JP (1) | JP6475623B2 (pt) |
CN (2) | CN104884077B (pt) |
AU (1) | AU2012392119B2 (pt) |
BR (1) | BR112015006656A8 (pt) |
CA (1) | CA2884051A1 (pt) |
RU (1) | RU2650635C2 (pt) |
WO (1) | WO2014056121A1 (pt) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013053076A1 (en) | 2011-10-10 | 2013-04-18 | Zensun (Shanghai)Science & Technology Limited | Compositions and methods for treating heart failure |
US10894815B2 (en) | 2012-10-08 | 2021-01-19 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Compositions and methods for treating heart failure in diabetic patients |
JP6568052B2 (ja) | 2013-05-22 | 2019-09-04 | ゼンサン (シャンハイ) サイエンス アンド テクノロジー,シーオー.,エルティーディー. | 心不全を治療するためのニューレグリンの徐放 |
CN110946993A (zh) | 2014-01-03 | 2020-04-03 | 上海泽生科技开发股份有限公司 | 纽兰格林制剂的配方 |
CN105497876B (zh) | 2014-09-24 | 2021-01-15 | 上海泽生科技开发股份有限公司 | 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物 |
CN111407882A (zh) | 2014-10-17 | 2020-07-14 | 上海泽生科技开发股份有限公司 | 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物 |
AR121035A1 (es) | 2019-04-01 | 2022-04-13 | Lilly Co Eli | Compuestos de neuregulina-4 y métodos de uso |
CN111840517A (zh) * | 2019-04-28 | 2020-10-30 | 上海泽生科技开发股份有限公司 | 神经调节蛋白用于长效预防、治疗或延迟心脏损伤的方法 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE463851B (sv) | 1988-09-02 | 1991-02-04 | Amsu Ltd | Komposition foer behandling av erektil dysfunktion via uretra |
US5530109A (en) | 1991-04-10 | 1996-06-25 | Ludwig Institute For Cancer Research | DNA encoding glial mitogenic factors |
US5716930A (en) | 1991-04-10 | 1998-02-10 | Ludwig Institute For Cancer Research | Glial growth factors |
US5834229A (en) | 1991-05-24 | 1998-11-10 | Genentech, Inc. | Nucleic acids vectors and host cells encoding and expressing heregulin 2-α |
DE4221256C2 (de) | 1992-06-26 | 1997-07-10 | Lancaster Group Ag | Galenische Zusammensetzung für die topische Anwendung |
US5741511A (en) | 1995-04-12 | 1998-04-21 | Sam Yang Co., Ltd. | Transdermal drug delivery device for treating erectile dysfunction |
US5912326A (en) | 1995-09-08 | 1999-06-15 | President And Fellows Of Harvard College | Cerebellum-derived growth factors |
US5941868A (en) | 1995-12-22 | 1999-08-24 | Localmed, Inc. | Localized intravascular delivery of growth factors for promotion of angiogenesis |
US5736154A (en) | 1996-03-11 | 1998-04-07 | Fuisz Technologies Ltd. | Transdermal delivery system |
SE9703226D0 (sv) | 1997-09-08 | 1997-09-08 | Astra Ab | New pharmaceutical composition |
US6770304B2 (en) * | 1997-11-10 | 2004-08-03 | Memorial Sloan-Kettering Cancer Center | Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol |
US6197801B1 (en) | 1998-01-14 | 2001-03-06 | Usa Doctors Products, Inc. | Injectable pharmaceutical composition for treatment and reversal of erectile dysfunction |
AUPP785098A0 (en) | 1998-12-21 | 1999-01-21 | Victor Chang Cardiac Research Institute, The | Treatment of heart disease |
US6635249B1 (en) * | 1999-04-23 | 2003-10-21 | Cenes Pharmaceuticals, Inc. | Methods for treating congestive heart failure |
AUPQ105799A0 (en) | 1999-06-18 | 1999-07-08 | Victor Chang Cardiac Research Institute, The | Cell growth inhibition |
WO2003099320A1 (en) | 2002-05-24 | 2003-12-04 | Zensun (Shanghai) Sci-Tech.Ltd | Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy |
US20070213264A1 (en) | 2005-12-02 | 2007-09-13 | Mingdong Zhou | Neuregulin variants and methods of screening and using thereof |
CA2841386A1 (en) | 2005-12-30 | 2007-07-12 | Zensun (Shanghai) Science & Technology Limited | Extended release of neuregulin for improved cardiac function |
CN101394861A (zh) * | 2005-12-30 | 2009-03-25 | 上海泽生科技开发有限公司 | 纽兰格林持续给药能改善心脏功能 |
US9580515B2 (en) | 2006-08-21 | 2017-02-28 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Neukinase, a downstream protein of neuregulin |
US20090156488A1 (en) | 2007-09-12 | 2009-06-18 | Zensun (Shanghai) Science & Technology Limited | Use of neuregulin for organ preservation |
JP5743898B2 (ja) | 2008-11-28 | 2015-07-01 | ゼンサン (シャンハイ) サイエンス アンド テクノロジー リミテッド | ニューレグリンペプチド及びその使用 |
CN102231987A (zh) | 2008-11-28 | 2011-11-02 | 上海泽生科技开发有限公司 | 纽兰格林和心脏干细胞 |
CN102470161A (zh) * | 2009-06-09 | 2012-05-23 | 上海泽生科技开发有限公司 | 神经调节蛋白用于治疗心力衰竭的有效剂量 |
WO2010142141A1 (en) * | 2009-06-09 | 2010-12-16 | Zensun (Shanghai) Science & Technology Limited | Neuregulin based methods for treating heart failure |
US20120121557A1 (en) | 2009-07-22 | 2012-05-17 | Children's Medical Center Corporation | Neuregulin induced proliferation of cardiomyocytes |
JP6096262B2 (ja) | 2009-08-25 | 2017-03-15 | ゼンサン (シャンハイ) サイエンス アンド テクノロジー,シーオー.,エルティーディー. | ニューレグリンに基づく心不全の治療方法 |
US10610489B2 (en) * | 2009-10-02 | 2020-04-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof |
CN102139095A (zh) | 2010-01-29 | 2011-08-03 | 上海泽生科技开发有限公司 | 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物 |
WO2013053076A1 (en) | 2011-10-10 | 2013-04-18 | Zensun (Shanghai)Science & Technology Limited | Compositions and methods for treating heart failure |
CN103127579B (zh) | 2011-11-21 | 2017-06-16 | 上海泽生科技开发股份有限公司 | 便携式注射泵的驱动*** |
US10894815B2 (en) | 2012-10-08 | 2021-01-19 | Zensun (Shanghai) Science & Technology, Co., Ltd. | Compositions and methods for treating heart failure in diabetic patients |
JP6568052B2 (ja) | 2013-05-22 | 2019-09-04 | ゼンサン (シャンハイ) サイエンス アンド テクノロジー,シーオー.,エルティーディー. | 心不全を治療するためのニューレグリンの徐放 |
CN104758300A (zh) | 2014-01-02 | 2015-07-08 | 上海泽生科技开发有限公司 | 维生素d及其组合物的抗菌用途 |
CN110946993A (zh) | 2014-01-03 | 2020-04-03 | 上海泽生科技开发股份有限公司 | 纽兰格林制剂的配方 |
CN105497876B (zh) | 2014-09-24 | 2021-01-15 | 上海泽生科技开发股份有限公司 | 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物 |
CN111407882A (zh) | 2014-10-17 | 2020-07-14 | 上海泽生科技开发股份有限公司 | 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物 |
CN111388682A (zh) | 2015-05-08 | 2020-07-10 | 上海泽生科技开发股份有限公司 | cMLCK基因导入 |
-
2012
- 2012-10-08 US US14/429,750 patent/US10894815B2/en active Active
- 2012-10-08 CA CA2884051A patent/CA2884051A1/en not_active Abandoned
- 2012-10-08 CN CN201280076130.2A patent/CN104884077B/zh active Active
- 2012-10-08 EP EP12886447.7A patent/EP2903632A4/en not_active Ceased
- 2012-10-08 CN CN201810331160.2A patent/CN109276705B/zh active Active
- 2012-10-08 JP JP2015534895A patent/JP6475623B2/ja active Active
- 2012-10-08 RU RU2015116264A patent/RU2650635C2/ru active
- 2012-10-08 WO PCT/CN2012/001353 patent/WO2014056121A1/en active Application Filing
- 2012-10-08 AU AU2012392119A patent/AU2012392119B2/en active Active
- 2012-10-08 BR BR112015006656A patent/BR112015006656A8/pt not_active Application Discontinuation
-
2020
- 2020-12-22 US US17/131,255 patent/US20210347840A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
US20150284440A1 (en) | 2015-10-08 |
WO2014056121A1 (en) | 2014-04-17 |
AU2012392119A1 (en) | 2015-04-09 |
EP2903632A4 (en) | 2016-07-13 |
CN109276705B (zh) | 2023-10-20 |
CA2884051A1 (en) | 2014-04-17 |
RU2650635C2 (ru) | 2018-04-16 |
EP2903632A1 (en) | 2015-08-12 |
AU2012392119B2 (en) | 2018-07-26 |
BR112015006656A2 (pt) | 2018-11-13 |
CN104884077A (zh) | 2015-09-02 |
CN104884077B (zh) | 2019-02-12 |
RU2015116264A (ru) | 2016-11-27 |
US20210347840A1 (en) | 2021-11-11 |
US10894815B2 (en) | 2021-01-19 |
JP2015532293A (ja) | 2015-11-09 |
JP6475623B2 (ja) | 2019-02-27 |
CN109276705A (zh) | 2019-01-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112015006656A8 (pt) | composições e métodos para o tratamento de insuficiência cardíaca em pacientes diabéticos | |
BR112018016001A2 (pt) | composição farmacêutica, métodos de tratamento e usos da mesma | |
BR112016012713A2 (pt) | Método para tratamento de câncer em um paciente necessitado, e, método de selecionar um paciente para um método de tratamento | |
BR112015003590A8 (pt) | Métodos para tratamento ou prevenção da asma por administração de um antagonista de il-4r | |
BR112015003397A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente. | |
WO2013169864A3 (en) | TETRAHYDRO[1,8]NAPHTHYRIDINE SULFONAMIDE AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORƴ AND THE TREATMENT OF DISEASE | |
BR112015003332A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
PH12015500274B1 (en) | Alkylpyrimidine derivatives for the treatment of viral infections and further diseases | |
EA201401028A1 (ru) | Фармацевтическая композиция, содержащая эмпаглифлозин и лекарственное средство от ожирения | |
BR112015003398A2 (pt) | composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
EA201490004A1 (ru) | Применение bifidobacterium lactis bl-04 для лечения заболеваний дыхательных путей | |
BR112016014830A2 (pt) | Conjugados de fármaco de anticorpo (adcs) com inibidores de ksp | |
BR112015027282A2 (pt) | fenfluramina para uso no tratamento de síndrome de dravet | |
GT201200313A (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
MY174727A (en) | Stable, protracted glp-1/glucagon receptor co-agonists for medical use | |
BR112015007985A8 (pt) | uso do carboidrato galactose denteada para preparação de composições para tratamento de nefropatia diabética e de distúrbios associados, e suas composições | |
BR112015006623A2 (pt) | laquinimod e pridopidina para o tratamento de doenças neurodegenerativas | |
BR112015006093A2 (pt) | combinação de rasagilina e pridopidine para o tratamento de desordens neurodegenerativas, particularmente na doença de huntington | |
BR112014030404A2 (pt) | proteína de fusão hgh-xten e seu uso no tratamento da deficiência de hormônio do crescimento | |
BR112019008384A2 (pt) | composição farmacêutica, processos para tratamento e seus usos | |
BR112017009552A8 (pt) | Métodos para alvejar o controle transcricional em regiões de super-realçador | |
CO7101244A2 (es) | Fenilimidazopirazoles sustituidos y su uso | |
BR112015010039A2 (pt) | tratamento de câncer com pomalidomida em um individuo com disfunção renal | |
BR112015000616A2 (pt) | tratamento da esclerose múltipla com combinação de laquinimode e fampridina | |
BR112015011099A2 (pt) | Composições e métodos para o tratamento de diplasia ectodérmica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25D | Requested change of name of applicant approved |
Owner name: SENSUN (SHANGHAI) SCIENCE AND TECHNOLOGY, CO., LTD. (CN) Owner name: SENSUN (SHANGHAI) SCIENCE AND TECHNOLOGY, CO., LTD |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: CIENCIA RELACIONADA COM O ART.229-C DA LPI (ANUENCIA PREVIA) (DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. ). |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |